Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 163 clinical trials
Rigosertib Plus Nivolumab for KRAS+ NSCLC Patients Who Progressed on First-Line Treatment

A Phase1/2a Study of Rigosertib plus Nivolumab in Stage IV Lung Adenocarcinoma Patients with KRAS Mutation who Progressed on First-Line Treatment

small cell lung cancer
kras
drug test
core needle biopsy
non-small cell lung cancer
  • 0 views
  • 19 Feb, 2024
  • 1 location
Cysteamine for Asthma

The purpose of this study is to see if a medicine called Cysteamine, given along with standard asthma care, will improve asthma symptoms and lung function.

allergen
prick skin
rhinitis
skin prick
eosinophil count
  • 14 views
  • 24 Nov, 2025
  • 1 location
First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b

Phase 1b, a study in high grade serous ovarian cancer and nonsmall cell lung cancer to evaluate the safety and clinical activity of the antibody-drug conjugate (ADC) XMT-1592.

measurable disease
ovarian cancer
peritoneal cancer
metastasis
primary peritoneal carcinoma
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Driving Pressure in Neurosurgery

Center of ventilation (COV) by EIT, as well as the lung ultrasonographyLUS), perioperative ventilatory parameters, arterial oxygenation index (PaO2/FiO2) , serum indicators and postoperative pulmonary complications are secondary outcome variables.

positive end expiratory pressure
oxygenation index
pulmonary complications
neurosurgery
  • 0 views
  • 19 Feb, 2024
  • 1 location
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers.

small cell lung cancer
blood test
drug test
venetoclax
metastatic nsclc
  • 0 views
  • 19 Feb, 2024
  • 39 locations
Durvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker Study

The main aim is to identify and describe biomarkers in different sample types related to chemoradiation followed by durvalumab treatment for stage III PD-L1 negative and positive non-small cell lung cancer (NSCLC) patients' eligible for curatively intended chemoradiation. The hypothesis is that clinical differences in course of disease reflect underlying …

liver metastasis
chemoradiotherapy
small cell lung cancer
platelet count
urine test
  • 0 views
  • 19 Feb, 2024
  • 2 locations
Dupilumab Asthma Sleep Study

Primary Objective: To assess the effect of dupilumab on sleep Secondary Objectives: To evaluate the effect of dupilumab on additional patient reported sleep outcomes To evaluate the effect of dupilumab on objective sleep assessment To evaluate the effect of dupilumab on asthma symptoms To evaluate the effect of dupilumab on …

forced expiratory volume
fractional exhaled nitric oxide
bronchodilator
eosinophil count
leukotriene receptor antagonist
  • 0 views
  • 24 Nov, 2025
  • 11 locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

liquid biopsy
carboplatin
BRAF
proto-oncogene tyrosine-protein kinase ros
pembrolizumab
  • 0 views
  • 19 Feb, 2024
  • 28 locations
Bioequivalence and the Tolerability and Antitumor Activity of Selinexor Combination Treatment

This is a Phase 1, two-part, two-arm, open-label study in patients with NSCLC who have had 1 or 2 prior lines of treatment, with 1 line containing a CPI, or patients with CRC who have had 2 prior lines of treatment (oxaliplatin- and irinotecan-based) and no prior immunotherapy. The study …

small cell lung cancer
kras
leucovorin
solid tumour
metastatic nsclc
  • 0 views
  • 19 Feb, 2024
  • 3 locations
Smartphone Application for Initiation of Protective Ventilation. Clinical Impact of Instrumental Dead Space Reduction

Clinical evaluation of a new educative tools (Smartphone application) based on impact of instrumental dead space reduction after initiation of protective ventilation during mechanical ventilation.

vasopressor
mechanical ventilation
assist control
  • 0 views
  • 19 Feb, 2024
  • 1 location